Efficacy of deferoxamine, N-acetylcysteine and selenium treatments in rats with Adriamycin-induced nephrotic syndrome.
BACKGROUND
Various experimental models related to Adriamycin (ADR)-induced nephropathy have been reported. The purpose of the present study was to evaluate the efficacy of N-acetylcysteine (NAC), deferoxamine (DFO) and selenium in protection against renal injury in ADR nephropathy.


METHODS
The study included 53 Sprague Dawley male rats. Nephrotic syndrome was induced by injection of ADR 5 mg/kg intravenously (n=46). Control rats (n=7) were injected with an equal volume of isotonic saline. After ADR administration, they were divided into a group given only ADR (n=17) and 3 antioxidant treatment groups: (i) NAC (n=10), (ii) DFO (n=10) and (iii) selenium (n=9). In both renal tissue and erythrocytes, oxidative system parameters and trace elements were determined.


RESULTS
Nephrotic syndrome was proven in ADR-injected rats 4 weeks after injections, with proteinuria, higher blood lipids and hypoalbuminemia. All of the antioxidant agents used in the present study to prevent the development of nephrotic syndrome provided benefits for the nephrotic state. Of them, selenium seemed to offer relatively lower and statistically insignificant efficacy for preventing proteinuria compared with the others.


CONCLUSIONS
Our results showed that concomitant administration of some antioxidants with ADR injections seems to have beneficial effects on clinical parameters even if antioxidants were given in a single dose. NAC and DFO are more effective than selenium to prevent renal injury.
Bulucu
F
F
Department of Internal Medicine, Gulhane Military Medical Academy, Ankara - Turkey.
Oktenli
C
C
Kenar
L
L
Ocal
R
R
Koc
B
B
Inal
V
V
Yamanel
L
L
Yaman
H
H
Sanisoglu
Y S
YS
Aydin
A
A
D000111:Acetylcysteine / Q000627:therapeutic use*; D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000633:toxicity; D003124:Colorimetry; D003404:Creatinine / Q000097:blood / Q000652:urine; D003676:Deferoxamine / Q000627:therapeutic use*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000633:toxicity; D004359:Drug Therapy, Combination; D004912:Erythrocytes / Q000187:drug effects / Q000378:metabolism; D016166:Free Radical Scavengers / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects / Q000378:metabolism; D008297:Male; D009404:Nephrotic Syndrome / Q000139:chemically induced / Q000188:drug therapy* / Q000378:metabolism; D018384:Oxidative Stress / Q000187:drug effects; D051381:Rats; D017207:Rats, Sprague-Dawley; D012643:Selenium / Q000627:therapeutic use*; D017262:Siderophores / Q000627:therapeutic use; D016896:Treatment Outcome
D000903:Antibiotics, Antineoplastic; D016166:Free Radical Scavengers; D017262:Siderophores; D004317:Doxorubicin; D003404:Creatinine; D012643:Selenium; D003676:Deferoxamine; D000111:Acetylcysteine